GlassScriptPhysician profile
Travis James Day
NPI 1659009199
$5,342.57
in general payments reported to CMS, 2019-2025
27 companies · $2,636 in 2025
The $2,636 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $410 · 2023: $1,501 · 2024: $794 · 2025: $2,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,932.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,144.88 | 2022-2025 | Cardiomems, Aveir, Gallant |
| Kestra Medical Technology Services, INC. | $1,047.75 | 2023-2025 | Assure Wcd |
| Medtronic, INC. | $719.09 | 2022-2025 | Corevalve Evolut R, Symplicity G3, Linq II |
| Astrazeneca Pharmaceuticals LP | $558.82 | 2022-2025 | Farxiga |
| Bard Peripheral Vascular, INC. | $319.53 | 2023-2025 | Venovo, Venclose Maven Catheter, Lutonix Drug Coated Balloon |
| Amgen INC. | $267.16 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.68 | 2023-2025 | Lifevest |
| Endologix LLC | $148.27 | 2025 | Endocross Device, Torus Stent Graft System |
| Biotronik INC. | $142.44 | 2025 | Acticor 7 Vr-T Dx |
| Abiomed | $123.92 | 2025 | |
| Daiichi Sankyo INC. | $93.50 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $75.84 | 2023-2024 | Verquvo |
| Cvrx, INC. | $68.91 | 2023 | Barostim Neo System |
| Boston Scientific Corporation | $55.22 | 2025 | Ranger, Watchman Flx |
| Chiesi USA, INC. | $50.53 | 2023-2025 | Cleviprex, Kengreal |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $47.07 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $37.39 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $36.40 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $35.86 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $32.61 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $29.15 | 2024 | Eliquis |
| Janssen Scientific Affairs, LLC | $24.37 | 2023 | Xarelto |
| Cardiva Medical, INC. | $23.12 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Convatec INC. | $21.61 | 2025 | |
| Atricure, INC. | $20.28 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.85 | 2023 | Jardiance |
| Itamar Medical INC | $10.32 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.